AGP Executive Report
Last update: a day agoCancer Tech: ASCO late-breaking results suggest a bioabsorbable radiation implant (GammaTile) after brain metastasis surgery may improve survival and reduce recurrence versus external beam radiation, with radiation timing delays a key clinical problem. Oncology Pipeline: Orion Pharma reported early Phase 1/2 data for TEAD inhibitor ODM-212 in advanced solid tumors, showing good tolerability and early response signals (including mesothelioma). Breast Cancer Surgery: SENOMAC trial results indicate omitting axillary lymph node dissection can be non-inferior for survival while cutting arm complications. Neuroendocrine Tumors: A secondary COMPETE analysis found 177Lu-edotreotide improved quality of life versus everolimus in unresectable GEP-NETs. Healthcare Access & Costs: Indiana’s ACA market is set to lose CareSource (and Cigna exits nationwide), leaving about 60,000 Hoosiers needing new coverage before 2027. Public Health: WHO chief Tedros visited eastern Congo amid a fast-moving Ebola outbreak, stressing community trust and safe burials. Mental Health & Tech: A report highlights concerns as some therapists use AI for recording/transcripts, raising trust and privacy alarms. Policy/Regulation: Three GOP AGs sued to block Trump’s medical cannabis rescheduling push for FDA-approved products and state-licensed programs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
